Skip to content
    Reviews

    Chemoimmunotherapy improves advanced OSCC survival in both sexes, review finds

    Sugiyama et alESMO Gastrointest Oncol

    A systematic review and meta-analysis evaluated sex-based overall survival (OS) outcomes in patients with untreated advanced oesophageal squamous cell carcinoma (OSCC) receiving first-line chemotherapy combined with immune checkpoint inhibitors (ICIs) compared with chemotherapy alone. Analyzing eight phase III randomized controlled trials comprising 4,904 patients (14.7% female), the investigation assessed whether biological sex influences treatment efficacy in this malignancy.
    Overall, chemotherapy plus ICIs significantly improved OS across the full patient cohort (hazard ratio [HR] 0.68, 95% CI 0.62–0.73). Stratified analysis demonstrated statistically significant OS improvements in both males (HR 0.68, 95% CI 0.63–0.74, I² = 0%) and females (HR 0.79, 95% CI 0.64–0.98, I² = 19%). Although subgroup evaluation revealed moderate heterogeneity (P = 0.19, I² = 42.8%), meta-regression analysis confirmed no significant interaction between biological sex and treatment benefit (P = 0.20). Sensitivity analysis further indicated that the observed survival advantage in female patients was largely driven by two individual trials. These findings support first-line chemoimmunotherapy regardless of patient sex, while highlighting a lower magnitude of benefit in females and the need to consider biological sex in trial design.

    Key Takeaways

    • First-line chemotherapy combined with immune checkpoint inhibitors significantly improved overall survival compared to chemotherapy alone in both male (HR 0.68, 95% CI 0.63–0.74) and female (HR 0.79, 95% CI 0.64–0.98) patients with advanced oesophageal squamous cell carcinoma.
    • Meta-regression analysis showed no statistically significant efficacy interaction by sex (P = 0.20), though sensitivity analysis indicated that the female survival benefit was driven predominantly by two of the eight analyzed trials.
    Read the original sourceESMO Gastrointest Oncol